Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
250.59
-0.41 (-0.16%)
Feb 21, 2025, 4:00 PM EST - Market closed
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
$1,070,592
Profits / Employee
-$132,456
Market Cap
32.44B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,230 | 130 | 6.19% |
Dec 31, 2023 | 2,100 | 98 | 4.90% |
Dec 31, 2022 | 2,002 | 337 | 20.24% |
Dec 31, 2021 | 1,665 | 212 | 14.59% |
Dec 31, 2020 | 1,453 | 130 | 9.83% |
Dec 31, 2019 | 1,323 | 258 | 24.23% |
Dec 31, 2018 | 1,065 | 316 | 42.19% |
Dec 31, 2017 | 749 | 235 | 45.72% |
Dec 31, 2016 | 514 | 145 | 39.30% |
Dec 31, 2015 | 369 | 113 | 44.14% |
Dec 31, 2014 | 256 | 91 | 55.15% |
Dec 31, 2013 | 165 | 36 | 27.91% |
Dec 31, 2012 | 129 | 13 | 11.21% |
Dec 31, 2011 | 116 | -56 | -32.56% |
Dec 31, 2010 | 172 | -6 | -3.37% |
Dec 31, 2009 | 178 | 8 | 4.71% |
Dec 31, 2008 | 170 | 41 | 31.78% |
Dec 31, 2007 | 129 | 7 | 5.74% |
Dec 31, 2006 | 122 | 28 | 29.79% |
Dec 31, 2005 | 94 | 23 | 32.39% |
Dec 31, 2004 | 71 | 11 | 18.33% |
Dec 31, 2003 | 60 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ALNY News
- 8 days ago - Alnylam: Waiting For Regulatory Updates In March - Seeking Alpha
- 8 days ago - Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress - Business Wire
- 23 days ago - Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 5 weeks ago - Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals - Business Wire
- 6 weeks ago - Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025 - Seeking Alpha
- 6 weeks ago - Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 3 months ago - Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference - Business Wire